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Available online 13 July 2019Background: The POP Trial was a phase 1, open-label, rising-dose, randomised study that explored the safety and
tolerability of calmangafodipir (superoxide dismutase mimetic) co-treatment with n-acetylcysteine (NAC) for
paracetamol overdose.
Methods: Patients were recruited at the Royal Inﬁrmary of Edinburgh (8th June 2017-10th May 2018). Inclusion
criterion: adults within 24 h of a paracetamol overdose that required NAC. Within each of 3 sequential cohorts,
participants were randomly assigned, with concealed allocation, to NAC and a single intravenous
calmangafodipir dose (n=6) or NAC alone (n=2). Calmangafodipir doseswere 2, 5, or 10 μmol/kg. Participants,
study and clinical teamswere not blinded. The primary outcomewas safety and tolerability. Secondary outcomes
were alanine transaminase (ALT), international normalised ratio (INR), keratin-18, caspase-cleaved keratin-18
(ccK18), microRNA-122, and glutamate dehydrogenase (GLDH). (Clinicaltrials.gov:NCT03177395).
Findings: All 24 participants received their allocated drug doses andwere analysed. Primary endpoints: all partic-
ipants experienced ≥1 adverse event (AE), most commonly gastrointestinal. Patients experiencing ≥1 serious
adverse event (SAE): NAC alone, 2/6; NAC + calmangafodipir (2 μmol/kg), 4/6; NAC + calmangafodipir
(5 μmol/kg), 2/6; NAC + calmangafodipir (10 μmol/kg), 3/6. No AEs or SAEs were probably or deﬁnitely
calmangafodipir-related. Secondary safety outcomes demonstrated no differences between groups. With NAC
alone, 2/6 had ALT N 100 U/L; with NAC + calmangafodipir, 0/18. No INR difference. Keratin-18 and ccK18
increased in the NAC alone group more than with calmangafodipir (baseline to 20 h fold change, NAC +
calmangafodipir (5 μmol/kg) compared to NAC alone: 0.48 (95%CI 0.28–0.83)). microRNA-122 changes were
similar to K18, GLDH was frequently undetected.
Interpretation: Calmangafodipir was toleratedwhen combined with NAC andmay reduce biomarkers of paracet-
amol toxicity.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).JamesWDear; Edinburgh Royal
EmmaEMorrison, Dr.Matthew
ee, Mr. Garry Milne, Ms. Lynsey
elle Steven, Prof Christopher J
gh (EMERGE): Ms. Polly Black,
rnadette Gallagher, Ms. Julia
s. Megan McGrath, Ms. Mary
aderanga, Ms. Miranda Odam,
arie Bengtson - PledPharma AB
is.henriksen@pledpharma.se;
l Eddleston, Dr. Robert Hunter,
-NC-ND license (http://creativecomm1. IntroductionParacetamol/acetaminophen (N-acetyl-p-aminophenol) is the most
commondrug taken in overdose in the United Kingdom (UK). Annually,
overdose directly leads to around 100,000 hospital attendances in the
UK with around half of these patients being admitted to hospital for
emergency antidote treatment [1]. Paracetamol is directly responsible
for the deaths of 100–150 people per year in the UK [2]. In the USA,
paracetamol overdose accounts for N56,000 hospital attendances and
around 450 deaths due to acute liver failure each year [3].
In overdose, the normal paracetamol detoxiﬁcation pathways are
overwhelmed which allows cellular injury to be produced by theons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Paracetamol overdose is a common reason for emergency admis-
sion to hospital and the commonest cause of acute liver failure in
Europe and North America. Acetylcysteine (NAC) is effective at
preventing liver injury if administered promptly, but it is substan-
tially less effective if started later than around 8 h after overdose.
We have previously demonstrated that a shorter 12 h NAC regi-
men (the ‘SNAP’ regimen) produces fewer adverse reactions
than the conventional 21 h protocol. The following Pubmed
search strategy “phase 1 AND trial AND acetaminophen AND
overdose” (10 March 2019) yielded no papers in this clinical
space aside from the protocol paper for our trial. The search “acet-
aminophen overdose” “phase 1” in clinicaltrials.gov only identified
our trial (10 March 2019). These search results demonstrate that
paracetamol overdose is neglected as a target for new drug devel-
opment despite being common and having a clear unmet clinical
need. In this phase 1 trial we combine a novel therapeutic agent
with the SNAP regimen.
Added value of this study
In this phase 1 study we explored the safety and tolerability of
calmangafodipir (a superoxide dismutase mimetic) co-treatment
with the SNAP NAC regimen. The combination of NAC and
calmangafodipir was safe and tolerated. There was evidence
from measurement of conventional and exploratory biomarkers
that the combination treatment may reduce liver injury biomarkers
more than NAC alone after paracetamol overdose.
Implications of all the available evidence
The current licenced treatment for paracetamol overdose is NAC.
When a patient develops liver injury there is no further therapeutic
option other than liver transplantation in severe cases. This trial
supports further development of calmangafodipir in robust clinical
trials that determine whether it is effective (clinically and econom-
ically) in patients at risk of paracetamol toxicity.
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(NAPQI). Animal data demonstrate that paracetamol-induced toxicity
broadly occurs in two phases: an initial metabolic phase followed by
an oxidative phase. In human patients the metabolic phase is predomi-
nantly during the ﬁrst 8 h after overdose with the oxidative phase dom-
inating thereafter. During themetabolic phase, paracetamolmetabolites
are conjugated in the liver. In the oxidative phase hepatocyte glutathi-
one (GSH) stores are depleted and NAPQI binds to intra-cellular pro-
teins causing increased oxidative stress, mitochondrial injury and cell
death [4].
Acetylcysteine (N-acetylcysteine; NAC) was developed as an anti-
dote for paracetamol poisoning in the 1970s [5]. It acts by replenishing
hepatocellular GSH to increase the detoxiﬁcation of NAPQI during the
metabolic phase of toxicity. Most commonly, patients receive an intra-
venous (IV) 21 h NAC regimen of 150 mg/kg over 1 h, then 50 mg/kg
over 4 h, then 100mg/kg over 16 h (total dose 300mg/kg) [5]. Although
highly effective at preventing paracetamol-induced hepatotoxicity
when used within 8 h of overdose, this regimen is associated with the
following challenges: (i) Reduced efﬁcacy when administered later
than around 8 h after overdose ingestion. However, there are data dem-
onstrating beneﬁt when administered to patients later than 8 h after
overdose [6]. (ii) Adverse drug reactions (ADRs): nausea/vomiting occursin more than half of recipients and anaphylactoid reactions in about a
third [7]. (iii) Prolonged duration: The regime is time consuming, taking
at least 21 h, leading to signiﬁcant hospital bed occupancy (around
47,000 bed days per year in England) [8].
To address the high incidence of ADRs and prolonged duration of the
standardNAC regimen, a shorter 12 h intravenous regimen has beende-
veloped (the ‘SNAP’ regimen) [9]. In this regimen the initial loading
dose (NAC 100mg/kg in 200mL) is given over 2 h, followed by a second
dose (200mg/kg in 1000mL) infused over 10 h (total dose of NAC same
as 21 h regimen). The SNAP regimenhas been demonstrated to be effec-
tive at reducing the incidence of vomiting and anaphylactoid reactions,
compared with the standard intravenous acetylcysteine schedule [9].
The SNAP regimen is as effective as the standard NAC regimen with re-
gard to preventing liver injury after paracetamol overdose [10].
In this studywe explored the safety and tolerability of combining the
SNAP regimen with a new therapeutic agent. Mangafodipir was origi-
nally developed as a MRI contrast agent and approved for that indica-
tion by the USA Food and Drug Administration (FDA) and the
European Medicines Agency (EMA). Mangafodipir has been demon-
strated to prevent paracetamol-induced liver injury in mice by acting
as a superoxide dismutase (SOD) mimetic which prevents mitochon-
drial injury during the oxidative phase of toxicity [11]. Consistent with
this mechanism of action, in mice, this protection is at a time point
when NAC is no longer active [11]. Calmangafodipir (Ca4Mn(DPDP)5),
is derived from mangafodipir, with 80% of the manganese in
mangafodipir being replaced with calcium. Based on the similarities be-
tween calmangafodipir and mangafodipir, it is anticipated that
calmangafodipir would also exhibit SOD-mimetic pharmacologic
actions similar to those of mangafodipir [12]. Calmangafodipir has
been studied in a Phase 2 safety and efﬁcacy study of chemotherapy-
induced peripheral neuropathy in patients with advanced metastatic
colorectal cancer (PLIANT Trial). As is the case with paracetamol toxic-
ity, a central mechanism of this neuropathy is oxidative stress. In the
PLIANT Trial calmangafodipir was well tolerated across three doses
(2, 5 and 10 μmol/kg) and prevented the development of
chemotherapy-induced peripheral neuropathy [13].
The primary objective of the POP Trial was to assess the adverse
events (AEs) and serious adverse events (SAEs) associated with
calmangafodipir co-treatment with the SNAP NAC treatment regime
in patients with paracetamol overdose. A secondary study objective
was the measurement of clinical and exploratory biomarkers of acute
liver injury.
2. Methods
2.1. Trial design
This study, EudraCT number 2017-000246-21, ClinicalTrials.gov
Identiﬁer NCT03177395, was funded by the Sponsor, PledPharma AB,
Stockholm, Sweden and was approved by the UK medicines regulator,
MHRA (25th April 2017) andWest of Scotland Research Ethics Commit-
tee 1, Glasgow, UK (11thApril 2017). The trial rationale and full protocol
have been published [14]. The following is a summary of the study
methods as per the CONSORT Guidelines. The study was an open label,
randomised, exploratory, rising dose design, NAC controlled, phase 1
safety and tolerability study in patients treated with NAC following
paracetamol overdose. There were no signiﬁcant changes to the proto-
col after trial commencement. This was a single centre study.
2.2. Participants
The inclusion criteria were: 1. Any patient with capacity admitted to
hospital within 24 h of either a single acute paracetamol overdose or
more than one dose of paracetamol (staggered) and deemed to require
treatment with NAC (as per contemporaneous UK guidelines provided
by the National Poisons Information Service via the Toxbase website).
425E.E. Morrison et al. / EBioMedicine 46 (2019) 423–4302. Provision ofwritten informed consent. 3.Males and females of at least
16 years of age. The exclusion criteria were: 1. Patients that do not have
the capacity to consent to participate in the study. 2. Patients detained
under theMental Health Act or deemed unﬁt by the Investigator to par-
ticipate due tomental health. 3. Patients with known permanent cogni-
tive impairment. 4. Patients who are pregnant or nursing. 5. Patients
who have previously participated in this trial. 6. Unreliable history of
overdose. 7. Patients presenting N24 h after overdose. 8. Patients who
take anticoagulants (e.g. warfarin) therapeutically or have taken an
overdose of anticoagulants. 9. Patients who, in the opinion of the re-
sponsible clinician/nurse, are unlikely to complete the full course of
NAC e.g. expressing wish to self-discharge. 10. Prisoners. 11. Non-
English speaking patients. Patients who took a mixed overdose that in-
cluded medications in addition to paracetamol were included in the
trial.2.3. Interventions
Study participantswere randomly assigned to receiveNAC and a sin-
gle dose of calmangafodipir, or NAC alone. This was performed in 3 se-
quential cohorts of 8 patients within which patients received NAC +
calmangafodipir (n = 6) or NAC alone (n = 2). The dose of
calmangafodipir used within each of the 3 cohorts was 2, 5, or 10
μmol/kg [13]. Overall, 24 patients were planned to be allocated as
follows: NAC alone (n = 6), NAC and calmangafodipir (2 μmol/kg)
(n = 6), NAC and calmangafodipir (5 μmol/kg) (n = 6), NAC and
calmangafodipir (10 μmol/kg) (n = 6).
Treatment startedwith a NAC IV infusion of 100mg/kg in 200mL sa-
line or 5% dextrose over 2 h. After this infusion was complete,
calmangafodipir was administered as a bolus IV infusion over 5 min at
the dose speciﬁed by the dosing cohort. Those patients randomised to
the NAC alone group had no intravenous injection. In all patients the
NAC regimen continued with 200mg/kg NAC diluted in 1000mL deliv-
ered IV over 10 h. As per local clinical practice, there is one blood sample
taken 2 h before the end of the second NAC bag (the 10 h time-point)
and a second blood sample taken 10 h later (the 20 h time-point).
NAC (at 200 mg/kg in 1000 mL IV over a further 10 h) was continued
if any of the following criteria were reached: ALT activity had more
than doubled since the admission measurement, OR ALT activity was
two times the upper limit of normal (100 U/L) ormore, OR international
normalised ratio (INR) was N1.3 OR paracetamol concentration
N 20 mg/L.2.4. Outcomes
Our primary objective was to determine the safety and tolerabil-
ity of calmangafodipir add-on treatment to the SNAP NAC treatment
regimen in patients treated for overdose. Therefore, the primary out-
come was the occurrence of any AEs or SAEs. Patients were followed
using their NHS Lothian electronic records. Primary outcome data
were collected 7, 30 and 90 days after randomisation, as were events
of special interest: representation to hospital (any reason), represen-
tation with liver injury, repeat overdose, death and transfer to liver
transplantation unit.
Secondary outcomes included clinical observations (pulse rate,
blood pressure, respiratory rate, pulse oximetry, temperature) and hae-
matological and clinical biochemistry parameters. Liver injury was
quantiﬁed by standard parameters (alanine transaminase (ALT) and
the international normalised ratio (INR)) and also the following explor-
atory circulating biomarkers: keratin-18 (K18), caspase cleaved K18
(ccK18), microRNA-122 (miR-122) and glutamate dehydrogenase
(GLDH). These outcomes were pre-deﬁned in detail in our study proto-
col. There were no signiﬁcant changes to the outcomes after trial
commencement.2.5. Sample size
Therewas no formal power calculation for this Phase 1 study. Six pa-
tients per group in this dose escalation study allowed initial exploration
of potential dose limiting toxicity.
An independent safety data monitoring committee (SDMC) evalu-
ated safety prior to each planned calmangafodipir dosing step increase
and recommended the continuation or termination of the study. During
recruitment, summary data of in-hospital mortality/morbidity and any
other information available on major outcome events (including SAEs
believed to be due to treatment) were supplied to the SDMC along
with any other data that the committee requested. The stopping guide-
lines determined that all further patient enrolment would be paused
pending advise if any of the following stopping rules were met: 1) Pa-
tient death, admission to a Critical Care Unit or admission to a Liver
TransplantationUnit due to any reason, or 2) One suspected unexpected
serious adverse reaction (SUSAR) that deﬁnitely or probably relates to
either calmangafodipir or NAC or both.
2.6. Randomisation and blinding
The allocation sequence for each dosing cohort was created by an
Edinburgh Clinical Trials Unit (ECTU) programmer (GM) using
computer-generated random numbers, using blocking to ensure the re-
quired 6:2 ratio. The randomisation list was held centrally at ECTU in
order to conceal treatment allocations until these were implemented
via the secure web-based randomisation system. There was no blinding
of participants or emergency department staff. The statistical analysis
plan was written blinded to the treatment allocations.
2.7. Biomarker measurement
ALT and INRweremeasured as part of routine clinical care in theBio-
chemistry Laboratory at the Royal Inﬁrmary of Edinburgh. Enzyme-
linked immunosorbent assay (ELISA) was used to measure K18 –
(Peviva M65 ELISA (classic)) and ccK18 (M30 Apoptosense ELISA,
Bioaxxess, Tewkesbury, UK). miR-122 was measured by reverse tran-
scription polymerase chain reaction (RT-PCR) as previously described
[15]. The concentration of miR-122 was expressed as the DCt using
spiked-in C. elegans miR-39 as an external normaliser and quantiﬁed
as copy number per μL by generating a standard curve [15]. GLDH was
measured by its oxogluterate reduction activity (Alpha Laboratories
Ltd., Eastleigh, UK). Biomarkersweremeasured in the Centre for Cardio-
vascular Science at the University of Edinburgh with the researcher
blinded to the treatment allocation.
2.8. Statistical analysis
A detailed statistical analysis planwas ﬁnalised before locking of the
trial database. This is detailed in the published protocol [14]. This initial
exploration of safety and tolerability of calmangafodipir did not apply
formal hypothesis tests; instead, 95% conﬁdence intervals are presented
where appropriate to indicate plausible effect sizes. The primary out-
come analysis reported the number and percentage of patients
experiencing an AE/SAE by randomised group and overall. Clinical ob-
servations and haematology and clinical biochemistry parameters
were summarised by measurement time point and change from base-
line. The ECG results were summarised by treatment group and overall
at 2.5, 10 and 20 h. Conventional and exploratory biomarkers were
summarised descriptively by treatment group and overall at baseline,
10 h and 20 h. Change from baseline was also summarised. Biomarkers
were analysed by treatment group and overall at each time point using
the mean and 95% conﬁdence interval. Biomarkers were compared be-
tween each calmangafodipir dose and the combined NAC alone group
using the difference in means and its 95% conﬁdence interval. Where
426 E.E. Morrison et al. / EBioMedicine 46 (2019) 423–430required, measures were log-transformed and reported by geometric
means and their ratio.
2.9. Role of the funder
Two investigators in this study were employed by PledPharma AB
(study funder). Their input was in study design (DH) and monitoring
(MB). The funder of the study had no role in data collection, data anal-
ysis, data interpretation, or writing of the paper. The corresponding au-
thor had full access to all the data in the study and had ﬁnal
responsibility for the decision to submit for publication. The corre-
sponding author wrote the paper.
3. Results
From 5th June 2017 to 10th May 2018 304 patients presenting with
acute poisoning were screened in the Emergency Department of the
Royal Inﬁrmary of Edinburgh (Fig. 1). Patients screened had toxicology
presentations that included, but were not exclusively, paracetamol
overdose. The main reasons for not being included were failure to
meet inclusion criteria (n = 216, predominately because patient was
not a paracetamol overdose that needed treatment) or due to meeting
an exclusion criteria (n = 39). Twenty-four patients were randomised
and all 24 received the full dosing of their allocated treatment. The
90 day follow up of the ﬁnal participant was completed on 8th August
2018 which was the protocol-deﬁned end-of-trial date. No patients
were lost to follow up.
The baseline demographics of the 4 treatment groups are presented
in Table 1. By chance, the NAC alone group reported ingestion of less
paracetamol (normalised to body weight) than the calmangafodipir
treated groups and had a lower median presentation paracetamolFig. 1. CONSORT diagramconcentration. By chance, the NAC alone group presented to hospital,
and started NAC treatment, an average of about 3 h later after overdose
than the calmangafodipir treated groups. In each treatment group the
following number of patients started treatment with NAC N 8 h after a
single overdose: NAC alone: 3/6; NAC + calmangafodipir (2 μmol/kg):
2/6; NAC + calmangafodipir (5 μmol/kg): 2/6; NAC + calmangafodipir
(10 μmol/kg): 1/6. Supplementary Fig. 1 represents graphically a post-
hoc analysis of the relation between the paracetamol concentration
and time from overdose for the single acute overdoses in this trial. The
majority of the study participants had co-ingested other agents (Sup-
plementary Table 1).
All randomised patients were analysed for the safety and tolerability
primary outcomes (Table 2). During the 7 days after randomisation 23
out of 24 patients had at least one AE. Eleven patients had at least one
SAE within the 90 day follow up period; 5 patients had at least one
SAE within 7 days of randomisation. These SAEs were spread across
the 4 treatment groups. Supplementary Table 2 presents the nature of
the AEs and SAEs. There were no AEs or SAEs judged to be probably or
deﬁnitely related to calmangafodipir. Seven patients experienced AEs
judged deﬁnitely related to NAC. Therewere no anaphylactoid reactions
to NAC. One death, that occurred 32 days after the start of NAC and
calmangafodipir (5 μmol/kg) treatment, was judged to be unrelated
to either NAC or calmangafodipir. There was one SUSAR reported
for calmangafodipir in the 10 μmol/kg cohort. The SUSAR was
hypokalaemia needing potassium replacement therapy that prolonged
the patient's hospital stay by 7 h. This was judged as probably related
to NAC and possibly related to calmangafodipir. Secondary outcomes
demonstrated no safety concerns for calmangafodipir in combination
with NAC (Supplementary Table 2).
Liver injury was explored with conventional (Table 3) and explor-
atory biomarkers (Table 4). The conﬁdence intervals for the fold changefor the POP Trial.
Table 1
Patient demographics. Patients were allocated to 4 treatment groups as described in the study protocol.
NAC
alone
NAC + 2 μmol/kg
calmangafodipir
NAC + 5 μmol/kg
calmangafodipir
NAC + 10 μmol/kg
calmangafodipir
(N = 6) (N = 6) (N = 6) (N = 6)
Age (years) at randomisation Mean (SD) 32.2 (12.5) 42.5 (13.1) 42.7 (12.7) 22.7 (3.3)
Median 30.0 41.0 42.5 22.0
Minimum, Maximum 19, 52 27, 66 26, 59 19, 28
Sex Male 4 (67%) 2 (33%) 2 (33%) 3 (50%)
Female 2 (33%) 4 (67%) 4 (67%) 3 (50%)
Time from ingestion of paracetamol to hospital presentation (hours) Mean (SD) 8.8 (6.2) 6.0 (6.2) 5.8 (7.2) 4.9 (5.2)
Median 7.6 2.6 2.1 2.1
Minimum, Maximum 1.9, 16.6 1.4, 15.1 1.3, 19.5 1.4, 14.6
Type of overdose Acute, ≤8 h to NAC 2 (33%) 4 (67%) 4 (67%) 4 (67%)
Acute, N8 h to NAC 3 (50%) 2 (33%) 2 (33%) 1 (17%)
Staggered intentional 0 (0%) 0 (0%) 0 (0%) 1 (17%)
Supra-therapeutic 1 (17%) 0 (0%) 0 (0%) 0 (0%)
Presentation paracetamol concentration (mg/L) Mean (SD) 76 (81) 127 (90) 74 (44) 127 (47)
Median 58 114 88 132
Minimum, Maximum 8, 228 16, 272 8, 117 76, 201
Total paracetamol ingested (mg/kg) Mean (SD) 185 (156) 235 (77) 229 (72) 397 (476)
Median 116 222 244 227
Minimum, Maximum 28, 418 154, 340 142, 303 88, 1357
Time from ingestion of paracetamol to start of NAC treatment (hours) Mean (SD) 12.1 (5.2) 9.8 (5.7) 10.2 (6.9) 8.6 (4.1)
Median 10.3 6.5 7.3 6.7
Minimum, Maximum 7.7, 20.3 5.5, 17.9 6.0, 23.8 5.3, 16.0
Time from ingestion of paracetamol to start of calmangafodipir (hours) Mean (SD) N/A 12.6 (6.8) 10.8 (4.1) 11.8 (5.4)
Median N/A 9.5 9.0 8.9
Minimum, Maximum N/A 8.5, 26.1 7.6, 18.0 7.6, 26.1
Any other drugs ingested Yes 5 (83%) 4 (67%) 5 (83%) 5 (83%)
No 1 (17%) 2 (33%) 1 (17%) 1 (17%)
Serum creatinine (μmol/L) Mean (SD) 74.7 (11.0) 67.5 (13.3) 67.3 (17.2) 69.5 (13.1)
Median 73.5 63.5 66.0 68.5
Minimum, Maximum 59, 92 57, 94 50, 98 53, 86
427E.E. Morrison et al. / EBioMedicine 46 (2019) 423–430from baseline to 20 h in ALT or INR included the null value (1) in all
treatment groups (Geometric mean of relative change (95%CI): NAC
alone: ALT 1.02 (0.62 to 1.69), INR 1.15 (0.98 to 1.35). NAC +
calmangafodipir (2 μmol/kg): ALT 0.83 (0.66 to 1.04), INR 1.07 (0.93
to 1.23). NAC + calmangafodipir (5 μmol/kg): ALT 0.87 (0.64 to 1.18),
INR 1.10 (1.03 to 1.18). NAC + calmangafodipir (10 μmol/kg): ALT
0.92 (0.57 to 1.49), INR 1.10 (1.00 to 1.21)). In the NAC alone group 2/
6 had an increase of 50% or more in ALT from baseline to 20 h. With
calmangafodipir 1/18 had this ALT increase (Supplementary Table 3).
In the NAC alone group 2/6 patients had an ALT activity N 100 U/L at
20 h after starting NAC, a clinically relevant value used to indicate
need for NAC treatment to continue (and a secondary outcome pre-
deﬁned in trial protocol). No patients in the calmangafodipir treated
groups reached this value (Supplementary Table 3). In total, in the
NAC alone group, 3 from 6 patients required additional NAC therapy
after the end of the SNAP regimen (1 from each of the following
overdose types: b8 h overdose to starting NAC, N8 h andTable 2
Primary outcome. Safety and tolerability was the primary outcome as judged by the occurrence
as described in the study protocol. The number of events and percentage of group experiencin
Event
Any adverse event
Any serious adverse event
Adverse event starting after commencement of NAC treatment and within 7 days of conse
Serious adverse event starting after commencement of NAC treatment and within 7 days o
Adverse event unrelated to NAC
Adverse event possibly related to NAC
Adverse event probably related to NAC
Adverse event deﬁnitely related to NAC
Adverse event unrelated to calmangafodipir
Adverse event possibly related to calmangafodipir
Adverse event probably related to calmangafodipir
Adverse event deﬁnitely related to calmangafodipirsupra-therapeutic). In the calmangafodipir groups, 2 out of 18 patients
required extended treatment (1 who took a staggered overdose and
another who started NAC treatment b 8 h after overdose). (Table 3).
Exploratory biomarkers have greater sensitivity than ALT in the context
of paracetamol-induced liver injury [16]. Circulating K18 and ccK18 in-
creased in concentration from baseline to 20 h in all 6 patients treated
with NAC alone (Geometric mean of relative change (95%CI): K18 1.85
(1.24 to 2.77); ccK18 2.22 (1.22 to 4.03)) (Table 4). This increase was
smaller in the calmangafodipir treated groups; the conﬁdence intervals
excluded the null value with the 5 μmol/kg calmangafodipir dose for
K18 and ccK18 (ratio of geometric means for the fold change from base-
line to 20 h (NAC + calmangafodipir compared to NAC alone) 2 μmol/
kg: K18 0.70 (95%CI 0.35 to 1.37), ccK18 0.67 (0.35 to 1.29); 5 μmol/
kg; K18 0.48 (0.28 to 0.83), ccK18 0.46 (0.22 to 0.96); 10 μmol/kg K18
0.76 (0.40 to 1.46) ccK18 0.48 (0.19 to 1.27)) (Supplementary Fig. 2).
In comparison to the K18 isoforms, miR-122 had similar mean and
median relative changes when NAC + calmangafodipir treatmentof adverse events and serious adverse events. Data are presented for each treatment group
g the event are listed.
NAC
alone
NAC + 2 μmol/kg
calmangafodipir
NAC + 5 μmol/kg
calmangafodipir
NAC + 10 μmol/kg
calmangafodipir
(N = 6) (N = 6) (N = 6) (N = 6)
6 (100%) 6 (100%) 6 (100%) 6 (100%)
2 (33%) 4 (67%) 2 (33%) 3 (50%)
nt 6 (100%) 5 (83%) 6 (100%) 6 (100%)
f consent 1 (17%) 1 (17%) 1 (17%) 2 (33%)
3 (50%) 5 (83%) 3 (50%) 5 (83%)
2 (33%) 2 (33%) 2 (33%) 2 (33%)
3 (50%) 2 (33%) 3 (50%) 2 (33%)
2 (33%) 3 (50%) 1 (17%) 1 (17%)
6 (100%) 6 (100%) 5 (83%) 6 (100%)
0 (0%) 4 (67%) 2 (33%) 2 (33%)
0 (0%) 0 (0%) 0 (0%) 0 (0%)
0 (0%) 0 (0%) 0 (0%) 0 (0%)
Table 3
Secondary outcome. Alanine transaminase activity (ALT) and international normalised ratio (INR) for each of the allocated treatment groups. Data are presented as mean or geometric
mean andmedian as per study protocol. The change from baseline to 20 h after starting NAC is presented as the relative change. A value of 1 indicates no change. SD= standard deviation.
GSD = geometric standard deviation. A patients received 12 h of treatment with acetylcysteine (NAC). The number of extra NAC infusions given to each group is listed.
NAC
alone
NAC + 2 μmol/kg
calmangafodipir
NAC + 5 μmol/kg
calmangafodipir
NAC + 10 μmol/kg
calmangafodipir
ALT (U/L) Baseline N 6 6 6 6
Geometric Mean (GSD) 42.5 (3.6) 24.6 (2.1) 29.4 (2.3) 17.7 (1.5)
Median 49.0 30.5 42.5 16.0
Minimum, Maximum 11, 209 9, 56 7, 67 12, 34
10 h N 6 6 6 6
Geometric Mean (GSD) 41.4 (3.3) 22.9 (1.8) 25.3 (2.1) 15.0 (1.3)
Median 48.0 28.0 32.5 14.5
Minimum, Maximum 11, 163 10, 44 8, 57 10, 24
20 h N 6 6 6 6
Geometric Mean (GSD) 43.3 (3.8) 20.4 (1.9) 25.4 (1.8) 16.4 (1.5)
Median 47.5 27.0 29.0 16.5
Minimum, Maximum 9, 226 8, 35 10, 53 8, 27
Relative change from baseline to 20 h - ratio Geometric Mean (GSD) 1.02 (1.62) 0.83 (1.25) 0.87 (1.34) 0.92 (1.58)
Median 0.79 0.78 0.80 0.83
Minimum, Maximum 0.70, 2.13 0.63, 1.11 0.60, 1.43 0.65, 2.08
INR Baseline Missing INR 0 1 0 0
N 6 5 6 6
Mean (SD) 1.02 (0.04) 1.00 (0.12) 0.98 (0.04) 1.05 (0.14)
Median 1.00 1.00 1.00 1.00
Minimum, Maximum 1.0, 1.1 0.9, 1.2 0.9, 1.0 0.9, 1.3
10 h N 6 6 6 6
Mean (SD) 1.30 (0.18) 1.17 (0.20) 1.20 (0.00) 1.22 (0.25)
Median 1.25 1.10 1.20 1.15
Minimum, Maximum 1.1, 1.6 1.0, 1.5 1.2, 1.2 1.0, 1.7
20 h N 6 6 6 6
Mean (SD) 1.18 (0.21) 1.07 (0.19) 1.08 (0.04) 1.17 (0.23)
Median 1.15 1.00 1.10 1.10
Minimum, Maximum 1.0, 1.5 0.9, 1.3 1.0, 1.1 1.0, 1.6
Relative change from baseline to 20 h - ratio # missing 0 1 0 0
N 6 5 6 6
Geometric Mean (GSD) 1.15 (1.17) 1.07 (1.12) 1.10 (1.07) 1.10 (1.10)
Median 1.15 1.00 1.10 1.10
Minimum, Maximum 1.00, 1.36 1.00, 1.30 1.00, 1.22 1.00, 1.23
Number of additional NAC infusions after 12 h regimen. None 3 (50%) 5 (83%) 6 (100%) 5 (83%)
One 1 (17%) 1 (17%) 0 (0%) 1 (17%)
Two 2 (33%) 0 (0%) 0 (0%) 0 (0%)
428 E.E. Morrison et al. / EBioMedicine 46 (2019) 423–430groups were compared to the NAC alone group (Table 4). miR-122 in-
creased in concentration from baseline to 20 h in patients treated with
NAC alone (geometric mean of relative change (95%CI): 1.48 (0.24 to
9.20)). This increase was consistently smaller across calmangafodipir
doses (ratio of geometric means for the fold change from baseline to
20 h (NAC + calmangafodipir compared to NAC alone) 2 μmol/kg:
0.33 (0.06 to 1.84); 5 μmol/kg; 0.71 (0.06 to 8.52); 10 μmol/kg 0.76
(0.12 to 4.95)). However, miR-122 had greater variability than K18 iso-
forms and all conﬁdence intervals included the null value (Supplemen-
tary Fig. 2).
GLDHwasmeasured as pre-deﬁned in our protocol. It was below the
published lower limit of quantiﬁcation (1 U/L) in 16 out of 72 samples.
As per our trial protocol, the GLDH analysis is presented in Supplemen-
tary Table 4 [17]. There was no difference between groups.
4. Discussion
Paracetamol overdose is a common reason for emergency hospital
admission. The only current treatment is NAC, but this antidote loses ef-
ﬁcacy when treatment is delayed. In this study we demonstrate that
calmangafodipir, in addition to NAC, did not result in any safety issues.
Calmangafodipir prevents cell injury by reducing oxidative stress – a
central mechanism responsible for paracetamol-induced hepatocyte
necrosis. It has been safely administered to patients with cancer and
demonstrated to reduce the incidence of peripheral neuropathy. In
this paper, we begin the process of exploring the clinical utility of
calmangafodipir in paracetamol overdose. As a starting point, it was im-
portant to determine whether there were any safety concerns whencombined with NAC, an agent that commonly produces ADRs. Our
data demonstrate no increase in AEs or SAEs at 3 ascending doses of
calmangafodipir when combined with the SNAP NAC regimen. An ad-
vantage of using the SNAP regimen in this trial, rather than the more
widely used 21 h NAC regimen, is it produces substantially fewer
ADRs. No patients in this trial had an anaphylactoid reaction yet these
reactions occur in up to 30% of those treated with the 21 h regimen
[9]. The improved safety proﬁle of the SNAP regimen facilitated our
analysis of any emergent calmangafodipir toxicity. From this phase 1
study we conclude that there are no safety issues that preclude, or
need special consideration in, future clinical trials.
Our pre-deﬁned secondary objective was to explore conventional
and exploratory biomarkers of liver injury. More patients in the NAC
alone group required additional NAC therapy after completion of the
SNAP regimen compared to the NAC + calmangafodipir groups due to
more patients having ALT increases. However, this phase 1 study is
small and noﬁrm conclusions can be drawnusingALT. In part, this is be-
cause early in the disease process - soon after overdose - ALT can remain
within the healthy reference interval despite evolving liver injury. The
exploration of liver injury in this trialwas facilitated by the recent devel-
opment of a panel of chemically and bio-analytically distinct biomarkers
for drug-induced liver injury. A full-length version of K18 is released by
necrotic cell death. A shorter, caspase cleaved form of K18 (ccK18) is re-
leased following cell apoptosis (programmed cell death). Both forms of
K18, when measured in the ﬁrst serum sample at presentation at the
hospital after paracetamol overdose, correlate with peak ALT activity
during that hospital stay [16,18]. K18 is more sensitive than ALT – it dis-
tinguishes patients with and without acute liver injury at hospital
Table 4
Secondary outcome. Keratin-18 (K18), caspase cleaved K18 (ccK18) and microRNA-122 (miR-122) for each of the allocated treatment groups. Data are presented as mean or geometric
mean andmedian as per study protocol. The change from baseline to 20 h after starting NAC is presented as the relative change. A value of 1 indicates no change. SD= standard deviation.
GSD=geometric standard deviation. The data formiR-122 are presented as the DCt using spiked-in C. elegansmiR-39 as an external normaliser and quantiﬁed as copy number per μL. The
DCt value is derived as Ct(miR-122)-Ct(miR-39)where Ct refers to the number of PCR cycles required to reach a threshold value for signal detection. Therefore, the lower theDCt value the
higher the concentration of miR-122.
NAC alone NAC + 2 μmol/kg
calmangafodipir
NAC + 5 μmol/kg
calmangafodipir
NAC + 10 μmol/kg
calmangafodipir
(N = 6) (N = 6) (N = 6) (N = 6)
K18 (U/L) Baseline (2 h) Geometric Mean (GSD) 187 (2.20) 177 (1.82) 193 (1.56) 128 (1.25)
Median 158 191 200 130
Minimum, Maximum 95, 731 91, 431 102, 353 89, 173
10 h Geometric Mean (GSD) 182 (1.95) 152 (1.56) 170 (1.42) 111 (1.18)
Median 172 135 168 110
Minimum, Maximum 91, 472 105, 319 113, 252 89, 143
20 h Geometric Mean (GSD) 347 (3.18) 229 (1.94) 172 (1.45) 181 (1.73)
Median 306 212 163 155
Minimum, Maximum 118, 2606 98, 572 100, 287 103, 507
Relative change from baseline to 20 h – ratio Geometric Mean (GSD) 1.85 (1.47) 1.29 (1.89) 0.89 (1.57) 1.41 (1.83)
Median 1.71 1.41 1.02 1.17
Minimum, Maximum 1.24, 3.57 0.53, 2.80 0.43, 1.45 0.74, 4.34
ccK18 (U/L) Baseline (2 h) Geometric Mean (GSD) 67 (1.99) 45 (1.33) 84 (1.80) 104 (2.44)
Median 61 45 71 83
Minimum, Maximum 28, 210 30, 67 52, 244 32, 408
10 h Geometric Mean (GSD) 72 (2.24) 53 (1.25) 56 (1.57) 78 (2.12)
Median 60 54 52 74
Minimum, Maximum 34, 281 36, 70 34, 99 33, 279
20 h Geometric Mean (GSD) 149 (3.34) 66 (1.34) 85 (1.62) 111 (2.56)
Median 111 69 94 113
Minimum, Maximum 51, 1451 38, 87 42, 148 38, 530
Relative change from baseline to 20 h - ratio Geometric Mean (GSD) 2.22 (1.77) 1.49 (1.55) 1.02 (1.79) 1.08 (2.44)
Median 1.85 1.29 0.94 1.03
Minimum, Maximum 1.48, 6.91 0.98, 2.88 0.52, 2.68 0.38, 3.27
miR-122 (DCt) Baseline (2 h) Mean (SD) 5.58 (3.36) 5.85 (1.50) 4.43 (3.92) 8.73 (2.36)
Median 5.17 5.89 4.47 8.71
Minimum, Maximum 1.93, 11.11 4.11, 8.18 −2.06, 8.82 5.52, 12.71
10 h Mean (SD) 5.41 (3.86) 6.14 (1.99) 5.01 (3.36) 9.00 (1.45)
Median 4.03 6.19 6.00 9.16
Minimum, Maximum 0.76, 10.93 2.94, 8.83 −1.06, 7.78 7.07, 10.73
20 h Mean (SD) 4.85 (3.97) 7.12 (2.26) 4.49 (2.93) 8.44 (1.50)
Median 4.37 7.42 5.72 8.56
Minimum, Maximum −0.04, 11.69 4.23, 9.67 −1.24, 6.58 5.94, 10.49
miR-122 (copies/mcL) Baseline (2 h) Geometric Mean (GSD) 146,363 (11.7) 116,749 (2.4) 194,075 (13.5) 36,051 (3.9)
Median 143,528 93,798 298,431 28,499
Minimum, Maximum 4871, 2,313,373 46,075, 421,291 12,405, 11,163,618 5892, 360,305
10 h Geometric Mean (GSD) 206,205 (13.0) 109,882 (3.3) 196,732 (9.4) 37,066 (2.2)
Median 351,346 97,112 125,977 31,463
Minimum, Maximum 9042, 6,819,168 32,464, 809,183 34,866, 10,717,356 14,955, 127,755
20 h Geometric Mean (GSD) 216,256 (10.8) 57,664 (3.8) 202,271 (7.7) 40,745 (3.2)
Median 349,165 42,716 96,912 33,750
Minimum, Maximum 4026, 4,488,868 11,394, 367,730 45,608, 10,150,008 7920, 198,075
Relative change from baseline to 20 h - ratio Geometric Mean (GSD) 1.48 (5.71) 0.49 (1.98) 1.04 (8.28) 1.13 (2.96)
Median 2.23 0.54 2.00 1.09
Minimum, Maximum 0.07, 10.91 0.22, 1.39 0.06, 10.55 0.30, 3.88
429E.E. Morrison et al. / EBioMedicine 46 (2019) 423–430presentation when ALT activity is still in the normal range. K18 is
supported for exploratory use in assessing drug-induced liver injury
in clinical trials, both by the EMA and the FDA [19,20]. miR-122 is a
microRNA biomarker speciﬁc for liver injury that is fully conserved
(translational) across in vitro models, in vivo models and humans.
Similar to K18, miR-122 is an early marker for acute liver injury
that predicts a rise in ALT activity following paracetamol overdose.
WhenmiR-122 wasmeasured at hospital presentation in patients re-
quiring NAC therapy its concentration correlated signiﬁcantly with
peak hospital stay ALT activity and miR-122 was signiﬁcantly higher
in those patients who developed subsequent acute liver injury
[16,18]. This is consistent with miR-122 having enhanced sensitivity
and speciﬁcity in this context-of-use.
The baseline measurements of the exploratory biomarkers were
similar across the 4 treatment groups consistent with successful
randomisation of patients with regard to the biomarker concentrations
prior to calmangafodipir administration. The variability across subjectswas substantially higher for miR-122 than K18, a limitation of miR-
122 that has been described in other studies [17]. All 6 patients in the
NAC alone group had an increase in both K18 forms from baseline to
20 h. In the calmangafodipir-treated groups there was not an increase
in the exploratory biomarkers.We note that GLDHwas too low to be re-
liably quantiﬁed in this study. This is consistentwithpublished evidence
that demonstrates GLDH has reduced sensitivity when directly com-
pared to K18 and miR-122 in patients with paracetamol overdose [14].
The data suggest that, with development, calmangafodipir may have
value as an additional therapy to NAC in patients at increased risk of
liver injury after paracetamol overdose. Such patients may include late
presenters after overdose (greater than around 8 h) or those with evi-
dence of liver injury at presentation. The exploratory biomarkers used
in this study can sensitively identify liver injury before ALT is elevated
and rapid clinical assayswould represent potential companion diagnos-
tics that could be used to identify patients that may beneﬁt from treat-
ment with calmangafodipir.
430 E.E. Morrison et al. / EBioMedicine 46 (2019) 423–4305. Limitations
None of the patients in this trial developed hepatotoxicity (ALT
N 1000 U/L) or acute liver failure. In future studies it will be important
to continue to monitor for any safety signals when calmangafodipir is
administered to patients with established liver injury and liver failure.
Liver injury after overdose is rare if NAC starts within 8 h of overdose.
The patients were not stratiﬁed at randomisation by their risk of devel-
oping liver injury. This, combined with the small patient numbers per
treatment group, resulted in the NAC alone group having a higher pro-
portion of patients who started NAC later than 8 h after overdose com-
pared with the NAC and calmangafodipir groups. This difference across
treatment groups should be considered when interpreting the effect of
calmangafodipir. It should be noted, however, that the change in bio-
markers was consistent in the NAC alone group regardless of overdose
type. All the NAC alone patients had an increase in K18 and ccK18
from baseline to 20 h including 2 early presenters (b8 h) and 1 supra-
therapeutic overdose patient. In 5 out of these 6 patients the concentra-
tion of K18 at 20 hwas greater than the published upper limit of normal
of the healthy reference interval (151 U/L) [17]. With caution, we spec-
ulate that this may be consistent with K18 reporting liver injury that is
too mild to cause an elevation in ALT. This hypothesis needs to be rigor-
ously studied in subsequent trials that robustly determine whether
calmangafodipir reduces paracetamol-induced liver injury biomarkers.
These future trialswould need to be large in size to demonstrate any im-
pact on patient mortality should that be present. However, it should be
feasible to demonstrate an effect on clinically and economically impor-
tant outcomes such as the development of liver synthetic dysfunction
and the length of hospital admission.
In conclusion, calmangafodipir was safe and tolerated in patients
treated with NAC for paracetamol overdose andmay reduce liver injury
biomarkers.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.07.013.
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